Aug 2010 to 2000 Residency Scheduling CoordinatorEnterprise Rent-A-Car Canton, MA Mar 2006 to Jul 2010 Account SupervisorPharmerica Brockton, MA Jun 2003 to Mar 2006 Billing RepresentativeKL Communications Newport, RI May 2005 to Nov 2005 Administrative & Marketing Assistant
Education:
Johnson & Wales University Providence, RI May 2005 Bachelor of Science in Sports/Entertainment/Event Management
Laguna BeachSales Executive at Prudential California Realty Your Oceanliving Lifestyles Realtor. 30 Miles of success serving San Clement to Newport Beach.
leeding risk in their labels, though Dr. Karen Mahoney, Deputy Director and Supervisory Medical Officer in FDAs Division of Nonprescription Drug Products, noted that a review of adverse event reports identified 41 cases of serious bleeding associated with these products between 1969 and August 2014.
Date: Jun 06, 2016
Category: Health
Source: Google
FDA Advises Wider Warnings on Most NSAID Medicines
In addition, FDA director of the division of nonprescription drug products, Dr. Karen Mahoney, says, Be careful not to take more than one product that contains an NSAID at a time, in the agencys announcement.She warns that people should always check the list of active ingredients in any drug fac
Date: Jul 10, 2015
Category: Health
Source: Google
FDA Strengthens Heart Attack, Stroke Warning for Popular Painkillers
"Be careful not to take more than one product that contains an NSAID at a time," Dr. Karen Mahoney, deputy director of the FDA's Division of Nonprescription Drug Products, said in the agency's announcement. People should check the list of active ingredients in the drug facts label if they aren't sur
Date: Jul 10, 2015
Category: Health
Source: Google
NSAID pain relievers' heart warnings boosted in US
ngredients in the drug facts label if theyaren't sure whether a product contains an NSAID and becareful not to take more than one product that containsan NSAID at a time,Dr. Karen Mahoney, deputy director ofthe FDA's Division of Nonprescription Drug Products, saidin the agency's announcement.
Date: Jul 10, 2015
Category: Health
Source: Google
Avandia review by FDA examines whether dangers were overdrawn
of metformin and sulfonylurea to control their diabetes. The pattern of judgments made by the company's researchers and reviewed by the Duke clinical trial specialists "does not suggest a fraudulent intent" to favor Avandia, Dr. Karen Mahoney, diabetes team leader for the FDA review, said Wednesday.
"The need for new therapies for Type 2 diabetes is not so urgent that one must tolerate a significant degree of uncertainty regarding serious risk concerns," wrote reviewer Dr. Karen Mahoney, in an agency memo obtained by Public Citizen.
Date: Apr 20, 2012
Category: Health
Source: Google
Youtube
Karen Mahoney, M.D.
Hoping to make a difference in the opioid overdose death crisis, FDA C...
Duration:
3m 42s
Karen Mahoney
This video is a tribute to Karen Mahoney on her retirement from Redbir...